Zacks.com on MSN2d
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug
Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...
Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma
Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...
Investing5d
EMA backs Regeneron's linvoseltamab for multiple myeloma
Multiple myeloma is the second most common blood cancer ... For investors tracking Regeneron's potential in this market, InvestingPro data shows the company's strong market position is supported ...
Regeneron announces EMA CHMP adopted positive opinion on linvoseltamab
Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has ...
Nasdaq5d
Regeneron's Linvoseltamab Receives Positive CHMP Opinion For Treating Relapsed/Refractory MM
(RTTNews) - Regeneron Pharmaceuticals ... for linvoseltamab in treating adults with relapsed and refractory or R/R multiple myeloma or MM. This recommendation applies to patients who have received ...
Morningstar5d
Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma
Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome ...